학술논문
IL-12/23-targeting in seborrheic dermatitis patients leads to long-lasting response.
Document Type
Article
Author
Source
Subject
*SEBORRHEIC dermatitis
*ANTIFUNGAL agents
*TOPICAL drug administration
*EXTERNAL ear
*EAR canal
*PATIENT experience
*
*
*
*
*
Language
ISSN
0340-3696
Abstract
1Images of patient 4 pre-ustekinumab treatment (A) and 31 months after starting ustekinumab treatment (B) In all patients, 3-5 doses of ustekinumab achieved complete or nearly complete SD clearance, except for one patient with particularly severe disease that necessitated 15 doses until full clinical resolution. Seborrheic dermatitis (SD) is an inflammatory skin disease that affects 50 million Americans of all ages, peaking in infancy and early adulthood [[1]]. [Extracted from the article]